ingineeon is a spin-off from the Technical University of Munich. Our mission at ingineeon is to bring breakthrough innovations to patients eagerly awaiting novel treatment options. To achieve this, we develop immunomodulatory next-generation biologics. Currently, our pipeline comprises 11 programs in R&D to late-stage preclincical development status in therapeutic areas such as infectious diseases, hepatology, inflammatory diseases and oncology.